⌘K

Home/Filings/4/0000950170-25-023592

4//SEC Filing

Freeman Roy Lester 4

Accession 0000950170-25-023592

CIK 0001750149other

View on SEC.gov Company Profile

Filed

Feb 18, 7:00 PM ET

Accepted

Feb 19, 8:16 PM ET

Size

21.3 KB

Accession

0000950170-25-023592

Insider Transaction Report

Form 4

Period: 2025-02-14

Inhibikase Therapeutics, Inc.IKT

Freeman Roy Lester

Director

Transactions

Award
Stock Option (Right to Buy)
2025-02-14+22,640→ 22,640 total
Exercise: $2.35Exp: 2035-02-14→ Common Stock (22,640 underlying)

Footnotes (1)

[F1]The options vested and became exercisable on February 14, 2025.

Documents

2 files

Issuer

Inhibikase Therapeutics, Inc.

CIK 0001750149

Entity typeother

Related Parties

1

filerCIK 0001799732

Filing Metadata

Form type: 4
Filed: Feb 18, 7:00 PM ET
Accepted: Feb 19, 8:16 PM ET
Size: 21.3 KB

View on SEC.gov